403 related articles for article (PubMed ID: 23578166)
1. Hypoglycemia observed during continuous glucose monitoring in patients with type 2 diabetes mellitus treated by subcutaneous insulin injection.
Ito H; Abe M; Shinozaki M; Oshikiri K; Yamashita H; Nakashima M; Takaki A; Yukawa C; Furusho M; Antoku S; Mifune M; Togane M
Diabetes Technol Ther; 2013 Jul; 15(7):586-90. PubMed ID: 23578166
[TBL] [Abstract][Full Text] [Related]
2. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
Pala L; Dicembrini I; Mannucci E
Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
[TBL] [Abstract][Full Text] [Related]
3. Insulin requirement profiles in Japanese hospitalized subjects with type 2 diabetes treated with basal-bolus insulin therapy.
Shimoda S; Okubo M; Koga K; Sekigami T; Kawashima J; Kukidome D; Igata M; Ishii N; Shimakawa A; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
Endocr J; 2015; 62(2):209-16. PubMed ID: 25392020
[TBL] [Abstract][Full Text] [Related]
4. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial.
Aronson R; Reznik Y; Conget I; Castañeda JA; Runzis S; Lee SW; Cohen O;
Diabetes Obes Metab; 2016 May; 18(5):500-7. PubMed ID: 26854123
[TBL] [Abstract][Full Text] [Related]
5. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
[TBL] [Abstract][Full Text] [Related]
7. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
8. A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.
Cengiz E; Sherr JL; Erkin-Cakmak A; Weinzimer SA; Burke EN; Sikes KA; Urban AD; Tamborlane WV
Endocr Pract; 2011; 17(6):862-6. PubMed ID: 21550949
[TBL] [Abstract][Full Text] [Related]
9. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose.
Su JB; Wang XQ; Chen JF; Wu G; Jin Y
Chin Med J (Engl); 2011 Jan; 124(1):144-7. PubMed ID: 21362322
[TBL] [Abstract][Full Text] [Related]
10. Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study.
Mathieu C; Storms F; Tits J; Veneman TF; Colin IM
Acta Clin Belg; 2013; 68(1):28-33. PubMed ID: 23627191
[TBL] [Abstract][Full Text] [Related]
11. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes.
Jovanovič L; Peters AL; Jiang HH; Hardin DS
Aging Clin Exp Res; 2014 Apr; 26(2):115-21. PubMed ID: 24092662
[TBL] [Abstract][Full Text] [Related]
12. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
13. Continuous subcutaneous insulin infusion and multiple dose of insulin regimen display similar patterns of blood glucose excursions in pediatric type 1 diabetes.
Alemzadeh R; Palma-Sisto P; Parton EA; Holzum MK
Diabetes Technol Ther; 2005 Aug; 7(4):587-96. PubMed ID: 16120030
[TBL] [Abstract][Full Text] [Related]
14. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
[TBL] [Abstract][Full Text] [Related]
15. An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study.
Blackberry ID; Furler JS; Ginnivan LE; Manski-Nankervis JA; Jenkins A; Cohen N; Best JD; Young D; Liew D; Ward G; O'Neal DN
Diabetes Res Clin Pract; 2014 Nov; 106(2):247-55. PubMed ID: 25271117
[TBL] [Abstract][Full Text] [Related]
16. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
[TBL] [Abstract][Full Text] [Related]
17. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
Dieuzeide G; Chuang LM; Almaghamsi A; Zilov A; Chen JW; Lavalle-González FJ
Prim Care Diabetes; 2014 Jul; 8(2):111-7. PubMed ID: 23953707
[TBL] [Abstract][Full Text] [Related]
19. Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi effect-more fiction than fact?
Choudhary P; Davies C; Emery CJ; Heller SR
Diabet Med; 2013 Aug; 30(8):914-7. PubMed ID: 23672623
[TBL] [Abstract][Full Text] [Related]
20. Real-time continuous glucose monitoring or continuous subcutaneous insulin infusion, what goes first?: results of a pilot study.
Moreno-Fernandez J; Gomez FJ; Gazquez M; Pedroche M; García-Manzanares A; Tenias JM; Benito P; Gomez IR
Diabetes Technol Ther; 2013 Jul; 15(7):596-600. PubMed ID: 23631604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
